Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
H股公告
Regulatory Filings Classification · 78% confidence The document is a Hong Kong listing rule announcement (“須予披露交易”) by RemeGen Co., Ltd. detailing its board approval and multiple agreements to use idle funds to purchase structured wealth management products from a bank. It is neither a financial statement (10-K/IR), management discussion (MDA), nor an operational transcript, dividend notice, share issue, nor proxy material. It is a routine regulatory announcement of a material transaction under the Listing Rules, therefore best classified under general regulatory filings.
2026-06-01 Chinese
H股公告
Regulatory Filings Classification · 85% confidence The document is an announcement under the Hong Kong Listing Rules (Chapter 14) notifying shareholders of a “disclosable transaction” – the company’s purchase of wealth management products with idle funds. It contains no financial statements or earnings data, nor is it a board change, report publication, dividend notice, or share issue. It is a regulatory announcement mandated by the exchange, so it falls into the general Regulatory Filings category (RNS).
2026-05-26 Chinese
H股公告
Regulatory Filings Classification · 90% confidence The document is a Hong Kong stock exchange announcement under the Listing Rules describing a discloseable transaction (purchase of wealth‐management products using idle funds) and the requisite board approvals and regulatory disclosures. It is a compliance announcement rather than a financial report, investor presentation, dividend notice, or share transaction. No actual financial statements are included. Therefore it falls under general regulatory filings (RNS).
2026-05-20 Chinese
荣昌生物关于召开2025年年度股东会的通知
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a formal notice to shareholders of the upcoming 2025 Annual General Meeting, including meeting date, agenda items to be voted on, voting procedures, and proxy form attachments. This is a solicitation of shareholder votes and provision of meeting information rather than the meeting materials themselves or voting results. Therefore it fits the Proxy Solicitation & Information Statement category.
2026-05-20 Chinese
H股公告
Regulatory Filings Classification · 35% confidence The document is a Hong Kong Stock Exchange disclosure under Chapter 14 of the Listing Rules describing the company’s board approval and details of the purchase of wealth‐management products. It is an announcement of a specific transaction and compliance with disclosure rules, not a full financial report, earnings release, AGM materials, or share issuance, and thus falls into the general Regulatory Filings category.
2026-05-19 Chinese
H股公告
Regulatory Filings Classification · 85% confidence The document is a supplemental disclosure announcement (“補充公告”) by a Hong Kong–listed company regarding its past purchases of wealth management products under HKEx Listing Rules. It provides additional transaction details, reasons for late compliance, and remedial measures. It is not a full financial report (e.g., Annual Report, Interim Report) nor a management discussion, earnings release, or investor presentation. Instead, it is a regulatory announcement regarding compliance with listing rules and reportable transactions. This falls under the general “Regulatory Filings” category (RNS).
2026-05-19 Chinese

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.